Morgan Stanley Discount Zert BNTX.../ DE000ME5DK67 /
| 8/28/2024 9:31:34 PM | Chg.+0.40 | Bid9:34:22 PM | Ask9:34:22 PM | Underlying | Strike price | Expiration date | Option type |
|---|---|---|---|---|---|---|---|
| 65.63EUR | +0.61% | 65.64 Bid Size: 2,500 |
- Ask Size: - |
BioNTech SE | - USD | 9/27/2024 | Call |
GlobeNewswire
8/16
Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program Against Influenza and C...
GlobeNewswire
8/14
Matinas BioPharma Reports Second Quarter 2024 Financial Results and Provides a Business Update
GlobeNewswire
8/1
Arbutus Reports Second Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
7/30
BioNTech Announces Positive Topline Phase 2 Results for mRNA Immunotherapy Candidate BNT111 in Patie...
GlobeNewswire
7/22
BioNTech to Report Second Quarter 2024 Financial Results and Corporate Update on August 5, 2024
GlobeNewswire
6/27
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the E...
GlobeNewswire
6/24
BioNTech and DualityBio Receive FDA Fast Track Designation for Antibody-Drug Conjugate Candidate BNT...
GlobeNewswire
6/1
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates M...
GlobeNewswire
5/29
BioNTech and CEPI Expand Partnership to Strengthen Africa’s mRNA Vaccine Ecosystem
GlobeNewswire
5/21
BioNTech to Present Clinical Data Updates for Next-Generation Immunotherapy Candidates at the ASCO A...
GlobeNewswire
5/21
Medigene's Global Research & Collaboration Agreement with BioNTech to Extend Beyond Initially Announ...
GlobeNewswire
5/17
BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2024
GlobeNewswire
5/17
Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business Updates
GlobeNewswire
5/9
Matinas BioPharma Reports First Quarter 2024 Financial Results and Provides a Business Update
